Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04934475 | MInimal Residual Disease Adapted Strategy(MIDAS) | active not recruiting | Phase 3 | 791 | Intergroupe Francophone du MyelomeNETWORK | 3 | Nov 7, 2024 | clinicaltrials |
| NCT04638790 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)(HL-Russia-1) | recruiting | Phase 3 | 300 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia |
| 2 |
| Sep 27, 2024 |
| clinicaltrials |
| NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma(POLAR BEAR) | recruiting | Phase 3 | 300 | Nordic Lymphoma GroupNETWORK | 7 | Sep 19, 2024 | clinicaltrials |
| NCT06573645 | A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | not yet recruiting | Phase 3 | 428 | Xia YiOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06475820 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis | active not recruiting | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT02131753 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | recruiting | Phase 2 / Phase 3 | 210 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06187441 | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)(HOVON174MM) | recruiting | Phase 3 | 599 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 606 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | recruiting | Phase 3 | 100 | Ruijin HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06520176 | Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 3 | 244 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06510530 | Astragalus for Symptomatic Alleviation in High-grade Lymphoma | not yet recruiting | Phase 3 | 60 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | recruiting | Phase 3 | 78 | Ruijin HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06465446 | A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma | not yet recruiting | Phase 3 | 202 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Jun 24, 2024 | clinicaltrials |
| NCT04061512 | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia(RAINBOW) | recruiting | Phase 2 / Phase 3 | 148 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06355401 | Maintenance Hormonal Therapy and DLBCL | not yet recruiting | Phase 2 / Phase 3 | 100 | Sohag UniversityOTHER | 0 | Apr 9, 2024 | clinicaltrials |
| NCT06314698 | Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease | not yet recruiting | Phase 3 | 478 | RenJi HospitalOTHER | 0 | Mar 18, 2024 | clinicaltrials |
| NCT06188676 | Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL | recruiting | Phase 3 | 100 | National Research Center for Hematology, RussiaNETWORK | 1 | Jan 3, 2024 | clinicaltrials |
| NCT00943423 | PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma(RAPID) | active not recruiting | Phase 3 | 602 | University College, LondonOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05328258 | Use of GnRHa During Chemotherapy for Fertility Protection(ProFertil) | recruiting | Phase 3 | 500 | Kenny Rodriguez-WallbergOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT05515029 | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis | active not recruiting | Phase 3 | 56 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05931263 | A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | recruiting | Phase 3 | 104 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT03948035 | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | active not recruiting | Phase 3 | 576 | Wuerzburg University HospitalOTHER | 2 | May 6, 2023 | clinicaltrials |
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | active not recruiting | Phase 3 | 462 | PETHEMA FoundationOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT04442412 | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy(FIL_PREVID) | recruiting | Phase 3 | 430 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05205902 | TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides(TOTEM-01) | not yet recruiting | Phase 3 | 78 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jan 25, 2022 | clinicaltrials |
| NCT04670029 | Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line(PHARAOM) | recruiting | Phase 3 | 186 | WepromOTHER | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT03647072 | PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy | recruiting | Phase 3 | 60 | Sherief Abd-ElsalamOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03562169 | The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd) | recruiting | Phase 3 | 406 | University of LeedsOTHER | 1 | Jun 19, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Nov 7, 2024source: clinicaltrials